$Moderna, Inc.(MRNA)$ $Moderna, Inc.(MRNA)$ $Merck(MRK)$ Morgan Stanley's ESMO takeaways go beyond just a positive melanoma trial. The independent discussant compared INT's RFS hazard ratio with adjuvant Herceptin's. Some physicians expressed confidence that the recurrence benefit would translate into longer overall survival. A KOL argued the effect was too large to be explained solely by general immune stimulation. Manufacturing turnaround is reportedly down to 30–40 days. RCC and bladder Phase 2 trials could have registrational potential, depending on results. More than a melanoma sto
$Applied Optoelectronics(AAOI)$ Over the past year alone, institutional ownership has seen an inflow of $2 billion compared to an outflow of roughly 10%. Institutional ownership now stands at more than 70%.
$Applied Optoelectronics(AAOI)$ Down a few percent over the weekend on 20-30k volume for Hyper, and the bears are celebrating. AI isn't dead, it's just pulling back to shake out weak hands. I'll add slowly on the way down. When it bounces, it'll be even more violent.
$SpaceX(SPCX)$ Only 2 of the Magnificent 7 did better over the same 4 months. From June 11 IPO pricing to the latest close: Microsoft +38.6% Meta +30.7% SpaceX +21.1% Apple +15.3% NVIDIA +10.5% Amazon +7.5% Alphabet -1.4% Tesla -5.3%